• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Desmopressin Acetate (DDAVP)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Desmopressin Acetate (DDAVP)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    The tablet formulation of DDAVP was approved for treatment of central diabetes insipidus (CDI). DDAVP is a synthetic analog of vasopressin, an antidiuretic hormone affecting renal water conservation.

    Currently, CDI can be treated with DDAVP in liquid form, delivered through a rhinal tube. Although the rhinal tube is a clinically effective treatment mode, DDAVP tablets offer a more convenient method of administration for those who must take the medication frequently.

    DDAVP tablets are absorbed from the intestine and circulated in an intact form, making it possible to achieve the desired antidiuretic effect.

    The onset of antidiuretic effect occurs at around one hour with DDAVP Tablets, and optimal antidiuretic effects last up to eight hours with doses of 0.1 mg to 0.2 mg, and up to 12 hours with a 0.4 mg dose. DDAVP tablets are supplied in 0.1 mg and 0.2 mg dosage strengths.

    Additional Information

    Diabetes insipidus is a rare metabolic disorder in which patients produce large quantities of dilute urine and are constantly thirsty. CDI is caused by a deficiency in the amounts of the hormone vasopressin secreted from the pituitary gland, and can be caused by disease of the gland, or by injury to the gland such as head trauma, surgery, or tumors. The condition can be acute and short in duration or it can be a chronic, life-long problem.

    According to the National Center for Health Statistics, there were 11,000 hospital discharges in the United States in 1992. The number of CDI subjects on therapy outside of the hospital setting is more difficult to measure.

    Approval Date: 1996-02-01
    Company Name: Rhone Poulenc Rorer
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing